<DOC>
	<DOC>NCT01621191</DOC>
	<brief_summary>The purpose of the study is to assess the safety and efficacy of duloxetine in participants with fibromyalgia at long-term use.</brief_summary>
	<brief_title>An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Participants who have completed the 15week treatment in the preceding study HMGZ Participants who wish continuous treatment with duloxetine after the preceding study Participants are able to give their own written consent Participants with serious cardiovascular, hepatic, renal, respiratory, or hematological disease, or clinically significant laboratory or electrocardiogram abnormality which indicate a serious medical problem or require significant intervention in the judgment of the investigators Participants with alanine aminotransferase/aspartate aminotransferase of not less than 100 International Units/Liter (IU/L) or total bilirubin of not less than 1.6 milligrams/deciliter (mg/dL) at Week 0 (Visit 8 of the preceding study) Participants with serum creatinine level of not less than 2.0 mg/dL, participant who has undergone kidney transplantation or hemodialysis at Week 0 (Visit 8 of the preceding study) Participants with pain difficult to discriminate from pain associated with fibromyalgia or disease which disturbs the assessment Participants with thyroidal dysfunction, excluding those assessed by the investigator that the disorder is controlled as appropriate by threemonth or longer drug therapy Participants with present or past history of rheumatoid arthritis, inflammatory arthritis, infectious arthritis, or auto immune disease rather than thyroid deficiency Participants with uncontrolled angle closure glaucoma Participants who received monoamine oxidase (MAO) inhibitors within 14 days before Week 0 (Visit 8 of the preceding study) or need to receive a MAO inhibitor within 5 days after study discontinuation Participants who have experienced suicidal ideation or suicide attempt during the preceding study Participants answering "yes" to any of the questions about active suicidal ideation/intent/behaviors occurring in the preceding study (Columbia Suicide Severity Rating Scale, Suicide Ideation section Questions 4 and 5; Suicidal Behavior section) Female participants who are pregnant, lactating, or who want to get pregnant during the study period. Male participants who want his partner to get pregnant Females of childbearing potential who cannot agree to utilize medically acceptable and reliable means of birth control during the study and for 1 month following the last dose of the study Participants assessed ineligible by the investigator (subinvestigator) for other reasons</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>